A brand new examine by the Indian Council of Medical Analysis (ICMR) has highlighted the rising burden of antimicrobial resistance (AMR) in India. The examine, performed throughout 20 tertiary-care hospitals, discovered that sufferers with drug-resistant bacterial infections face greater mortality, longer hospital stays and considerably greater remedy prices than these contaminated with drug-sensitive strains.
Researchers analysed the medical information of almost 1.6 lakh hospitalised sufferers between April 2022 and April 2025. The findings, revealed in The Lancet Regional Well being – Southeast Asia, examined infections attributable to 4 main Gram-negative micro organism: Escherichia coli (E. coli), Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa. Amongst 26,213 sufferers with confirmed infections attributable to these micro organism, 61.1% had infections proof against carbapenem antibiotics.
Carbapenem Resistance Linked to Larger Mortality
The examine discovered that carbapenem-resistant infections constantly resulted in greater mortality than vulnerable infections. For Klebsiella pneumoniae, mortality reached 31.2% amongst sufferers with resistant infections, in contrast with 23.5% amongst these with vulnerable infections. Equally, mortality for E. coli stood at 24.4% versus 17.3%. The distinction was additionally evident in different bacterial infections. Mortality amongst sufferers with Acinetobacter baumannii infections was 37.9% for resistant strains in contrast with 32.8% for vulnerable strains. For Pseudomonas aeruginosa, the corresponding figures have been 28.9% and 20.2%. Furthermore, essentially the most extreme outcomes occurred in infections proof against carbapenems, with mortality charges starting from 46.4% to 50.8%.
Drug Resistance Will increase Healthcare Prices
Antimicrobial resistance additionally locations a major monetary burden on sufferers and healthcare programs. In response to the examine, remedy prices for drug-resistant infections have been 1.1 to 2 occasions greater than these for vulnerable infections. For instance, remedy for drug-resistant E. coli averaged $420 per affected person, in contrast with $211 for vulnerable infections. Equally, the prices for Okay. pneumoniae have been $587 versus $505, whereas A. baumannii remedy value $655 in contrast with $436. For P. aeruginosa, the typical remedy value reached $702 for resistant infections, in contrast with $510 for vulnerable infections.
Resistant Infections Result in Longer Hospital Stays
Sufferers with drug-resistant infections additionally spent extra time in hospital. These with resistant E. coli infections stayed a median of 23.1 days, in contrast with 17.8 days for sufferers with vulnerable infections. Dr Kamini Walia, Senior Scientist at ICMR and an writer of the examine, stated that antimicrobial resistance is already having a major affect on sufferers and healthcare in India. She famous that carbapenem-resistant infections carry considerably greater mortality and remedy prices.
Stronger Antibiotics Alone Can not Remedy AMR
Nevertheless, researchers careworn that merely creating or prescribing stronger antibiotics won’t be sufficient to handle the antimicrobial resistance disaster. As a substitute, efficient AMR administration requires a mix of higher an infection prevention, well timed analysis and accountable antibiotic use. Applicable antibiotic remedy is especially vital as a result of pointless or inappropriate use can get rid of vulnerable micro organism whereas permitting resistant micro organism to outlive and multiply. Moreover, incomplete or inappropriate antibiotic remedy can speed up the event and unfold of resistance.
ICMR Strengthens Antimicrobial Resistance Surveillance
ICMR has monitored antimicrobial resistance by way of its Antimicrobial Resistance Surveillance and Analysis Community (AMRSN) since 2013. The company has highlighted AMR as a significant healthcare problem as a result of it may possibly result in extended sickness, greater healthcare prices and elevated mortality. In response, ICMR is specializing in strengthening AMR surveillance, an infection prevention and fast diagnostic capabilities. The organisation can also be exploring various approaches to remedy, together with rising choices corresponding to bacteriophages and monoclonal antibodies.
Tackling India’s Rising Superbug Risk
The findings underline the pressing want for a complete technique to fight drug-resistant infections in India. By combining stronger infection-control measures, sooner diagnostics, efficient surveillance and accountable antibiotic use, healthcare suppliers can enhance remedy outcomes and assist gradual the unfold of antimicrobial resistance. As reported by healthandme.com, the examine demonstrates that AMR just isn’t merely a future menace. It’s already growing mortality, hospital stays and healthcare prices, making well timed motion important for safeguarding sufferers and strengthening India’s healthcare system.
